BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, Phase I/II clinical study of BPB-101 as monotherapy in
patients with advanced solid tumors to evaluate the safety, pharmacokinetic characteristics
and antitumor activity of BPB-101.